BioWorld1h
Merck opts in for global license of Abbisko’s pimicotinib for $85M
Merck KGaA is exercising its option for a global license to commercialize Abbisko Therapeutics Co. Ltd.’s pimicotinib for $85 million. As previously reported by BioWorld, Abbisko out-licensed China ...
Houston-area company may be developing next hot weight-loss drug
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
Fierce Biotech7h
Merck Group pays $85M to nab global rights for Abbisko's rare tumor drug after phase 3 win
With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...
Phase 2 trial reveals potential of DPP-1 inhibitor for bronchiectasis
The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...
Indiatimes15m
Sun Pharma Adv Res. - Sun Pharma Advanced Research Company Share Price
Rights Mar 16, 2016 Mar 17, 2016 May 12, 2015 Rights ratio: 5 share for every 116 held at a price of Rs 245.0 Rights Aug 23, 2012-Jul 14, 2011 Rights ratio: 1 share for every 7 held at a price of Rs ...